Maravai Historical Cash Flow

MRVI Stock  USD 5.37  0.06  1.10%   
Analysis of Maravai Lifesciences cash flow over time is an excellent tool to project Maravai Lifesciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 102.7 M or Begin Period Cash Flow of 663.7 M as it is a great indicator of Maravai Lifesciences ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Maravai Lifesciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Maravai Lifesciences is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

About Maravai Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Maravai balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Maravai's non-liquid assets can be easily converted into cash.

Maravai Lifesciences Cash Flow Chart

As of now, Maravai Lifesciences' Begin Period Cash Flow is increasing as compared to previous years. The Maravai Lifesciences' current Dividends Paid is estimated to increase to about 250.8 M, while Sale Purchase Of Stock is projected to decrease to (21 K).

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Change In Working Capital

The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.

Dividends Paid

The total amount of dividends that a company has paid out to its shareholders over a specific period.
Most accounts from Maravai Lifesciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Maravai Lifesciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
As of now, Maravai Lifesciences' Begin Period Cash Flow is increasing as compared to previous years. The Maravai Lifesciences' current Dividends Paid is estimated to increase to about 250.8 M, while Sale Purchase Of Stock is projected to decrease to (21 K).
 2021 2023 2024 (projected)
Capital Expenditures14.9M65.6M68.8M
Dividends Paid153.5M176.5M250.8M

Maravai Lifesciences cash flow statement Correlations

0.62-0.12-0.5-0.83-0.33-0.1-0.190.160.02-0.09-0.120.24-0.73-0.05-0.070.14-0.990.1-0.10.1
0.62-0.55-0.85-0.36-0.23-0.250.330.10.1-0.05-0.130.43-0.44-0.33-0.280.18-0.580.06-0.060.06
-0.12-0.550.320.36-0.55-0.45-0.46-0.74-0.750.46-0.49-0.490.46-0.15-0.54-0.80.2-0.440.42-0.44
-0.5-0.850.320.220.120.65-0.64-0.04-0.080.3-0.08-0.710.250.770.45-0.140.45-0.310.3-0.31
-0.83-0.360.360.22-0.12-0.280.11-0.57-0.420.39-0.31-0.330.73-0.2-0.41-0.530.87-0.380.37-0.38
-0.33-0.23-0.550.12-0.120.370.560.860.83-0.840.940.58-0.210.040.770.860.210.79-0.790.79
-0.1-0.25-0.450.65-0.280.37-0.430.520.430.010.16-0.36-0.330.930.810.46-0.01-0.030.03-0.03
-0.190.33-0.46-0.640.110.56-0.430.370.47-0.690.650.870.08-0.73-0.020.480.190.66-0.660.66
0.160.1-0.74-0.04-0.570.860.520.370.9-0.830.850.6-0.630.20.850.99-0.290.77-0.780.77
0.020.1-0.75-0.08-0.420.830.430.470.9-0.790.820.6-0.470.10.810.91-0.130.85-0.60.85
-0.09-0.050.460.30.39-0.840.01-0.69-0.83-0.79-0.95-0.880.410.33-0.54-0.840.18-0.960.93-0.96
-0.12-0.13-0.49-0.08-0.310.940.160.650.850.82-0.950.75-0.25-0.170.660.860.020.9-0.90.9
0.240.43-0.49-0.71-0.330.58-0.360.870.60.6-0.880.75-0.35-0.660.140.66-0.270.84-0.840.84
-0.73-0.440.460.250.73-0.21-0.330.08-0.63-0.470.41-0.25-0.35-0.21-0.47-0.590.81-0.40.38-0.4
-0.05-0.33-0.150.77-0.20.040.93-0.730.20.10.33-0.17-0.66-0.210.590.12-0.02-0.340.33-0.34
-0.07-0.28-0.540.45-0.410.770.81-0.020.850.81-0.540.660.14-0.470.590.8-0.060.54-0.430.54
0.140.18-0.8-0.14-0.530.860.460.480.990.91-0.840.860.66-0.590.120.8-0.260.79-0.790.79
-0.99-0.580.20.450.870.21-0.010.19-0.29-0.130.180.02-0.270.81-0.02-0.06-0.26-0.180.18-0.18
0.10.06-0.44-0.31-0.380.79-0.030.660.770.85-0.960.90.84-0.4-0.340.540.79-0.18-0.81.0
-0.1-0.060.420.30.37-0.790.03-0.66-0.78-0.60.93-0.9-0.840.380.33-0.43-0.790.18-0.8-0.8
0.10.06-0.44-0.31-0.380.79-0.030.660.770.85-0.960.90.84-0.4-0.340.540.79-0.181.0-0.8
Click cells to compare fundamentals

Maravai Lifesciences Account Relationship Matchups

Maravai Lifesciences cash flow statement Accounts

201920202021202220232024 (projected)
Sale Purchase Of Stock(227K)(1.5B)1.7M0.0(20K)(21K)
Change To Inventory106K(19.1M)(21.6M)9.5M649K681.5K
Investments(17.1M)6.1M105.7M(267.6M)(127.9M)(121.5M)
Change In Cash2.8M211.5M315.1M80.9M(57.2M)(54.3M)
Net Borrowings(2.6M)196.9M(6M)(5.4M)(4.9M)(4.7M)
Stock Based Compensation1.7M24.6M10.5M18.7M34.6M36.3M
Free Cash Flow7.0M126.8M353.7M518.9M60.7M57.6M
Change In Working Capital2.3M35.9M(176.6M)(45.1M)97.8M102.7M
Begin Period Cash Flow21.9M24.7M236.2M551.3M632.1M663.7M
Total Cashflows From Investing Activities(17.1M)6.1M105.7M(267.6M)(240.9M)(228.8M)
Other Cashflows From Financing Activities(1.3M)773.7M(153.0M)(182.1M)(55.3M)(52.5M)
Depreciation24.1M25.8M24.8M38.1M48.8M33.7M
Other Non Cash Items2.4M(7.5M)(6.2M)(8.7M)(690.9M)(656.4M)
Capital Expenditures17.1M25.4M14.9M17.1M65.6M68.8M
Total Cash From Operating Activities24.1M152.2M368.6M536.0M126.2M221.3M
Change To Account Receivables(1.9M)(33.1M)(70.4M)(22.3M)84.4M88.6M
Change To Operating Activities1.5M9.7M(17.5M)(23.6M)(21.2M)(20.2M)
Net Income(5.2M)78.8M469.3M490.7M(119.0M)(113.1M)
Total Cash From Financing Activities(4.2M)53.2M(159.0M)(187.5M)(61.1M)(64.1M)
End Period Cash Flow24.7M236.2M551.3M632.1M575.0M374.2M
Change To Netincome477K(340K)45.8M320.0M368.0M386.4M
Change To Liabilities2.6M78.4M(7.3M)(8.7M)(7.8M)(7.4M)

Currently Active Assets on Macroaxis

When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Maravai Lifesciences Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.33)
Earnings Share
(1.67)
Revenue Per Share
2.044
Quarterly Revenue Growth
(0.03)
Return On Assets
(0.02)
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.